Navigation Links
Skinvisible Patent Granted in Australia

- Invisicare Patents Continue to be Granted Globally

LAS VEGAS, June 3 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website:, the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia. The Invisicare patent provides protection in the areas of "Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using".

(Logo: )

This patent will assist Skinvisible's sales efforts in Australia by protecting its Invisicare technology and formulated products. Invisicare has a unique ability to hold active ingredients on the skin for extended periods of time while resisting wash-off, rub-off and perspiration. This benefit leads to additional unique enhancements to topical dermatology products. Additionally, Invisicare provides product life-cycle management by allowing for new patent protection for products coming off patent and providing improved claims to formulations of cosmetics, over-the-counter and prescription skincare products.

"The demand for our Invisicare technology and out products is international. A key component of our business strategy is to provide patentable products to our clients," said Mr. Terry Howlett, President and CEO of Skinvisible. "Having our Invisicare patent approved in Australia is one more degree of protection that we can provide to our international licensees. We continue to submit for patent protection worldwide for all products formulated with Invisicare."

Australia has followed India as the second international patent approved for Skinvisible. With numerous patents pending both for its technology and formulated products, Skinvisible continues to remain focused on securing licensees for its products internationally.

About Invisicare(R)

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See:

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See:

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007).

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154


SOURCE Skinvisible Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
Breaking Biology News(10 mins):